ViewRay, Inc.: insider trades · United States · SEC (Form 4)

About ViewRay, Inc.

ViewRay, Inc. (ticker: VRAY) is a U.S.-based medical technology company that has been listed on the NASDAQ Global Market, and it is best understood as a focused oncology-radiotherapy specialist rather than a broad healthcare platform. The company started operations in 2004 as a Florida corporation, was later reincorporated in Delaware in 2007, and evolved into its current corporate structure after the acquisition of the operating business of ViewRay Technologies. Its corporate headquarters are in Oakwood Village, Ohio, United States, which underscores its industrial and regulatory base in the U.S. market.([sec.gov](https://www.sec.gov/Archives/edgar/data/1597313/000162828022003905/vray-20211231.htm?utm_source=openai)) ViewRay’s core business is the design, manufacture, and commercialization of MRIdian, an MRI-guided radiation therapy platform. The system is intended to image the tumor and surrounding tissue while radiation is being delivered, helping clinicians adapt treatment in real time to changes in anatomy and tumor position. In practical terms, the technology is aimed at improving precision in cancer care and supporting treatment of challenging indications such as lung, liver, pancreatic, and prostate cancers. This makes ViewRay a niche technology vendor in a high-value segment of oncology equipment, with a product strategy centered on a single differentiated platform rather than a diversified device portfolio.([sec.gov](https://www.sec.gov/Archives/edgar/data/1597313/000119312518159378/d479909ds3.htm?utm_source=openai)) From a competitive standpoint, ViewRay operates in a small but strategically important corner of the radiation oncology market. Its historical differentiation has been the combination of MRI and radiation delivery in a clinical system, which the company described in filings as the only clinical MRI-guided radiation therapy system on the market. That positioning gives ViewRay a clear technological identity, but it also exposes the business to intense execution risk, including hospital purchasing cycles, clinical adoption, reimbursement dynamics, and the capital intensity required to scale installations and support customers.([sec.gov](https://www.sec.gov/Archives/edgar/data/1597313/000119312518159378/d479909ds3.htm?utm_source=openai)) Geographically, ViewRay is rooted in the United States but serves an international customer base. Public announcements and filings indicate deployments and treatments across North America, Europe, and Asia, showing that the company’s commercial opportunity is global even if its headquarters and primary corporate base remain in Ohio. One notable milestone highlighted in public materials is that 10,000 patients had been treated with the MRIdian system, a useful signal of clinical traction and installed-base growth.([nasdaq.com](https://www.nasdaq.com/press-release/10000th-patient-receives-treatment-with-viewrays-mridian-system-2020-09-01?utm_source=openai)) Recent public disclosures also suggest a business still navigating a demanding operating environment. ViewRay’s SEC filings have emphasized risks around commercialization, backlog conversion, funding needs, supply chain timing, and general market conditions. In other words, the company combines meaningful technological relevance in cancer treatment with a highly sensitive financial profile. For investors in France, Belgium, and Switzerland, VRAY should therefore be viewed as a specialized U.S. NASDAQ healthcare name with potential upside tied to adoption of MRIdian, but also with material operational and financing risk.([sec.gov](https://www.sec.gov/Archives/edgar/data/1597313/000156459021011089/vray-10k_20201231.htm?utm_source=openai))